
Oncology Based In-Vivo CRO Market by Services (Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies), Indication (Hematological Malignancies, Rare Cancer, Solid Tumor), End-User - Global Forecast 2024-2030
Description
Oncology Based In-Vivo CRO Market by Services (Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies), Indication (Hematological Malignancies, Rare Cancer, Solid Tumor), End-User - Global Forecast 2024-2030
The Oncology Based In-Vivo CRO Market size was estimated at USD 1.27 billion in 2023 and expected to reach USD 1.41 billion in 2024, at a CAGR 11.34% to reach USD 2.70 billion by 2030.
Global Oncology Based In-Vivo CRO Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Oncology Based In-Vivo CRO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Oncology Based In-Vivo CRO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Oncology Based In-Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Altogen Labs, Cellvax, SAS, Charles River Laboratory, Crown Bioscience, Cyagen Biosciences, Evotec SE, Explicyte by Immusmol SAS Company, Icon PLC, Imavita, IVRS AB, Laboratory Corporation of America Holdings, Melior Discovery, Noble Life Sciences, Pharmaron, Pharmatest Services, Reaction Biology by Copeba, Redoxis AB, Taconic Biosciences, Inc., The Jackson Laboratory, and XenTech.
Market Segmentation & Coverage
This research report categorizes the Oncology Based In-Vivo CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:
Services
Biomarker Development
Clinical Trial Management
Pharmacokinetics Studies
Preclinical Studies
Indication
Hematological Malignancies
Rare Cancer
Solid Tumor
End-User
Academic & Research Institutes
Biotechnology Companies
Pharmaceutical Companies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Oncology Based In-Vivo CRO Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Oncology Based In-Vivo CRO Market?
3. What are the technology trends and regulatory frameworks in the Oncology Based In-Vivo CRO Market?
4. What is the market share of the leading vendors in the Oncology Based In-Vivo CRO Market?
5. Which modes and strategic moves are suitable for entering the Oncology Based In-Vivo CRO Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Oncology Based In-Vivo CRO Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing incidence of cancer and need for effective drug discovery
- 5.1.1.2. Rising need for optimized and efficient oncology clinical trial activities
- 5.1.1.3. Government initiatives encouraging personalized medicine
- 5.1.2. Restraints
- 5.1.2.1. Concerns associated with data security and privacy
- 5.1.3. Opportunities
- 5.1.3.1. Advancements in oncology-based in-vivo technologies with data analytics and AI
- 5.1.3.2. Expansion of oncology CRO services for biomarker development
- 5.1.4. Challenges
- 5.1.4.1. Limitations of regulatory compliance of oncology trials
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Oncology Based In-Vivo CRO Market, by Services
- 6.1. Introduction
- 6.2. Biomarker Development
- 6.3. Clinical Trial Management
- 6.4. Pharmacokinetics Studies
- 6.5. Preclinical Studies
- 7. Oncology Based In-Vivo CRO Market, by Indication
- 7.1. Introduction
- 7.2. Hematological Malignancies
- 7.3. Rare Cancer
- 7.4. Solid Tumor
- 8. Oncology Based In-Vivo CRO Market, by End-User
- 8.1. Introduction
- 8.2. Academic & Research Institutes
- 8.3. Biotechnology Companies
- 8.4. Pharmaceutical Companies
- 9. Americas Oncology Based In-Vivo CRO Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Oncology Based In-Vivo CRO Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Oncology Based In-Vivo CRO Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Altogen Labs
- 13.1.2. Cellvax, SAS
- 13.1.3. Charles River Laboratory
- 13.1.4. Crown Bioscience
- 13.1.5. Cyagen Biosciences
- 13.1.6. Evotec SE
- 13.1.7. Explicyte by Immusmol SAS Company
- 13.1.8. Icon PLC
- 13.1.9. Imavita
- 13.1.10. IVRS AB
- 13.1.11. Laboratory Corporation of America Holdings
- 13.1.12. Melior Discovery
- 13.1.13. Noble Life Sciences
- 13.1.14. Pharmaron
- 13.1.15. Pharmatest Services
- 13.1.16. Reaction Biology by Copeba
- 13.1.17. Redoxis AB
- 13.1.18. Taconic Biosciences, Inc.
- 13.1.19. The Jackson Laboratory
- 13.1.20. XenTech
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ONCOLOGY BASED IN-VIVO CRO MARKET RESEARCH PROCESS
- FIGURE 2. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2023 VS 2030
- FIGURE 3. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ONCOLOGY BASED IN-VIVO CRO MARKET DYNAMICS
- FIGURE 7. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
- FIGURE 8. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 10. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 12. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.